Healthcare - Biotechnology - NASDAQ - US
$ 26.63
-5.06 %
$ 3.91 B
Market Cap
-12.05
P/E
INCOME STATEMENT
0
REVENUE
-283 M
OPERATING INCOME
-259 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Immunovant, Inc.
| Revenue | 0 |
| Cost Of Revenue | 231 K |
| Gross Profit | -231 K |
| Operating Expenses | 283 M |
| Operating Income | -283 M |
| Other Expenses | -23.4 M |
| Net Income | -259 M |
Income Statement
Millions
| Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 | |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||
| Cost Of Revenue | 0.2 | 1.3 | 1.2 | 1.0 | 21 K | 0 | 0 |
| Gross Profit | (0.2) | (1.3) | (1.2) | (1.0) | 21 K | 0 | 0 |
| OPERATING INCOME | |||||||
| Operating Expenses | 282.7 | 208.3 | 156.0 | 108.1 | 66.1 | 448 | 136.7 |
| Selling, General and Administrative Expenses | 57.3 | 48.0 | 54.2 | 39.5 | 18.2 | 448 | 1.5 |
| Research and Development Expenses | 212.9 | 160.3 | 101.8 | 68.6 | 47.9 | 25.7 | 135.3 |
| Operating Income | (282.7) | (198.5) | (156.2) | (107.8) | (65.7) | 450 | (136.7) |
| PRE-TAX INCOME | |||||||
| Interest Income Expense | 0 | 12.5 | 0.7 | 0 | 0.6 | 0 | 0 |
| Total Other Income | 23.9 | (2.7) | (0.8) | 0.3 | (2.5) | 0 | 116 |
| Pre-Tax Income | (258.8) | (211.0) | (156.8) | (107.8) | (66.3) | 448 | (136.7) |
| NET INCOME | |||||||
| Tax Provision | 0.6 | 9 K | 84 K | (0.4) | 97 K | 19 K | 0 |
| Net Income | (259.3) | (211.0) | (156.7) | (107.4) | (66.4) | 448 | (136.7) |
| EPS | 1.88 | 1.71 | 1.43 | 1.22 | 1.54 | 0 | 13.7 |